Researchers seek to improve success of chimeric antigen receptor-T cell therapy in non-Hodgkin lymphoma

A study published by researchers from Mayo Clinic Cancer Center at Mayo Clinic in Florida and Case Western, Cleveland Medical Center, investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor-T cell therapy (CAR-T cell therapy). The study is published in Cancer Discovery.

This article was originally published on MedicalXpress.com

Read More: